Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

Results showed GNSC-001 met the primary safety endpoint and was well-tolerated in all study subjects, including 12-month follow-up. Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement. Osteoarthritis affects more than 30…